Latest news with #MarcoFregenal
Miami Herald
07-07-2025
- Business
- Miami Herald
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, July 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: FTHM: In an exclusive interview, Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's disruptive approach to real estate services through its proprietary, technology-driven platform. Fregenal highlights Fathom's flat-fee commission model, which empowers agents to retain more of their earnings while enabling industry-leading retention and rapid national expansion. With operations in 43 states and a network of over 14,700 agents, Fathom is scaling efficiently through its virtual model, integrated ancillary services, and strategic acquisitions, including the recent addition of My Home Group. He also addresses Fathom's innovative Bitcoin strategy and strong financial performance, including a 32% year-over-year revenue increase in Q1 2025, positioning the Company to capture additional market share amid an improving housing market. Pete O'Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company's pioneering work in fibroblast-based cell therapies. O'Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company's robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders. FTHM and FBLG are clients of RedChip Companies. Please read our full disclosure at About Fathom Holdings Inc. Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ --END-- SOURCE: RedChip Companies, Inc. (Media Suite)
USA Today
03-07-2025
- Business
- USA Today
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, July 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: In an exclusive interview, Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's disruptive approach to real estate services through its proprietary, technology-driven platform. Fregenal highlights Fathom's flat-fee commission model, which empowers agents to retain more of their earnings while enabling industry-leading retention and rapid national expansion. With operations in 43 states and a network of over 14,700 agents, Fathom is scaling efficiently through its virtual model, integrated ancillary services, and strategic acquisitions, including the recent addition of My Home Group. He also addresses Fathom's innovative Bitcoin strategy and strong financial performance, including a 32% year-over-year revenue increase in Q1 2025, positioning the Company to capture additional market share amid an improving housing market. Pete O'Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company's pioneering work in fibroblast-based cell therapies. O'Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company's robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders. FTHM and FBLG are clients of RedChip Companies. Please read our full disclosure at About Fathom Holdings Inc. Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: 'Discovering Tomorrow's Blue Chips Today'™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave Gentry RedChip Companies Inc. 1-407-644-4256 info@ –END– SOURCE: RedChip Companies, Inc. (Media Suite) View the original press release on ACCESS Newswire
Associated Press
03-07-2025
- Business
- Associated Press
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, July 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: In an exclusive interview, Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's disruptive approach to real estate services through its proprietary, technology-driven platform. Fregenal highlights Fathom's flat-fee commission model, which empowers agents to retain more of their earnings while enabling industry-leading retention and rapid national expansion. With operations in 43 states and a network of over 14,700 agents, Fathom is scaling efficiently through its virtual model, integrated ancillary services, and strategic acquisitions, including the recent addition of My Home Group. He also addresses Fathom's innovative Bitcoin strategy and strong financial performance, including a 32% year-over-year revenue increase in Q1 2025, positioning the Company to capture additional market share amid an improving housing market. Pete O'Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company's pioneering work in fibroblast-based cell therapies. O'Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company's robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders. FTHM and FBLG are clients of RedChip Companies. Please read our full disclosure at About Fathom Holdings Inc. Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: 'Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave Gentry RedChip Companies Inc. 1-407-644-4256 [email protected] --END-- SOURCE: RedChip Companies, Inc. (Media Suite) press release
Yahoo
14-05-2025
- Business
- Yahoo
Q1 2025 Fathom Holdings Inc Earnings Call
Marco Fregenal; President, Chief Executive Officer, Chief Financial Officer, Director; Fathom Holdings Inc Daniel Weinmann; Vice President of Finance; Fathom Holdings Inc Darren Aftahi; Managing Director, Senior Research Analyst; Roth Capital Partners LLC Operator Good day, everyone, and welcome to the Fathom Holdings' Inc. first-quarter 2025 conference call. (Operator Instructions) It is now my pleasure to turn the floor over to your host, [Paul Kuntz]. Sir, the floor is yours. Thank you, and good afternoon. Welcome to Fathom Holdings' first-quarter 2025 conference call. Joining us today is the company's CEO, Marco Fregenal; and VP of Finance, Daniel Weinmann. Before I turn the call over to management, I want to remind listeners that today's call may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to numerous conditions, many of which are beyond the company's control, including those outlined in the Risk Factors section of the company's Form 10-K and other company filings made with the SEC, copies of which are available on the SEC's website at As a result of those forward-looking statements, actual results could differ materially. Fathom undertakes no obligation to update any forward-looking statements after today's call, except as required by law. Please note that during the call, we will discuss adjusted EBITDA, a non-GAAP financial measure as defined by SEC Regulation G. A reconciliation of this non-GAAP financial measure to the most directly comparable GAAP measure is included in today's press release, which is now posted on Fathom's website. And with that, I will now turn the call over to Fathom's CEO, Marco Fregenal. Please proceed. Marco Fregenal Thank you, Paul. Good afternoon, everyone, and thank you for joining us on today's call. I am pleased to welcome you to Fathom Holdings First Quarter 2025 Earnings Conference. Before diving into the numbers, I'm going to begin by recognizing the continued dedication and perseverance of our entire Fathom team, our agents, employees and leadership. The first quarter brought ongoing economic headwinds from elevated mortgage rates to shifting global economic uncertainty, all impacting by our behavior. But through it all, our team remained focused in our strategy remains clear. The results we are sharing today are a direct reflection of the discipline and execution. We enter 2025 with measure optimism, and I am proud to say we exceeded public expectations. Revenue growth was strong. Transaction volume increased, agent count continued to rise and will be analyst estimates by a meaningful margin. We also continue our cost-cutting initiatives, reducing expenses by approximately that $750,000 per quarter going forward. These efforts are helping us build what we believe will be a more efficient and scalable business. We now expect to achieve adjusted EBITDA profitability in the second quarter, a significant milestone and a testament to the progress we made over the past year. Now let's take a look at our earnings for Q1. Total revenue rose $32.1 million -- 32.1% to $93.1 million compared to $70.5 million in the same period last year. The performance exceeded analysts' expectations by roughly 12%, demonstrating our ability to grow despite broader economic and industry uncertainty. Brokerage revenue climbed nearly 36% to $88.9 million, up from $65.4 million last year. We entered the quarter with approximately 14,750 licensed agents a 22.8% increase over Q1 of 2024. Transactions increased by 26%, which approximately 9,715 [closing] this quarter. Gross profit improved to $8.1 million, up 13% year-over-year. Excluding Dagley Insurance, which we divested in 2024, our gross profit growth was 34% from $6 million in Q1 of 2024, highlighting the strength of our core brokers engine. Now let me shift to Elevate our most significant strategic initiative to date. Elevate powered by our (inaudible) intelliAgent platform is a high-margin growth program designed to enhance agent productivity, scale our platform and drive long-term profitability. It is a concierge-level (inaudible) offering that provides a comprehensive services, including robust marketing and lead generation, lead conversion, transaction coordination, expert coaching, recruiting support and much more. All of this is delivered by a dedicated team, so our agents can focus entirely on serving their clients. Agents who enroll contribute a 20% commission split along with the standard transaction fee. That's incredibly competitive when you consider that many agents already pay similar or higher split at traditional brokerages just to hang their license with limited support behind it. Our goal with Elevate is to bridge the gap that so many agents experience. While most want to reinvest in their own growth, many simply don't have the time, tools or the know-how to do so. Elevate is designed to remove that friction by giving them the infrastructure, marketing resources and business coaching, they need to scale their businesses efficiently and affordably. Since our soft launch just 4 weeks ago, we have seen over 120 agents sign up for the program. While we require that an agent must have completed at least 4 transactions in the past 12 months to qualify for the program, the agents who have signed up so far have an average annual production of between 9 to 10 closings per year. Participating agents are projected to generate a significant increase in gross profit per transaction and EBITDA per transaction. By the fourth quarter, we aim to be onboarding around 100 new agents per month into the program. We're also developing targeted extensions of their programs such as Elevate for teams and Elevate for partners to meet growing demand. Additionally, we are in early-stage conversations with external organizations interested in licensing Elevate, further underscoring the industry-wide potential of this program. What makes all of this possible is intelliAgent as the engine behind Elevate, it streamlines operations, minimizes overhead and enable us to deliver high touch, high-impact services at a price point that most traditional brokers simply cannot match. Combined with our overall low-cost business model, we believe that gives a significant competitive edge and create a sustainable and scalable path for growth, both for Fathom and for our agents. Although the program is in infancy, we believe the Elevate may also have some positive impact in our ancillary businesses as we build a much closer relationship with agents participating in the program. Now let's turn briefly to review market conditions. While mortgage rates remain elevated, they have begun to show signs of stabilizing as the housing market shift from a seller's market toward a more balanced or buyers market. One clear indicator of this shift is the increase in housing inventory across key markets. For example, in March, inventories rose by 16% in California, 20% in Utah, 28% in Colorado and 18% in Georgia. As inventories levels climb, we're seeing a rise in the number of listings with price reductions and extended days of the market. This has led to home prices flattening or experiencing modest year-over-year declines. For instance, average home prices have dropped year-over-year by 2.4% in Florida, 4% in Colorado, 8% in Kansas and 5% in Illinois. While there are still many uncertainties, we believe Fathom is well positioned to benefit from even a modest improvement in market activity, driven by our lean cost structure and compelling value proposition to our agents. Now let's review our ancillary businesses. Mortgage revenue increased 13% to $2.6 million for the first quarter of 2025, up from $2.3 million in the first quarter of 2024. We have seen an expected increase in [file] stars for the month of April, which typically indicates the early stage of the seasonal increase in the market. Title revenue increased 43% to $1 million for the first quarter of 2025, up from $700,000 for the first quarter of 2024. File Stars for the month of April, thus far have increased by over 45% year-over-year. Together, we believe these businesses are enhancing our margins, increase agent retention and contributing to a more diverse and durable revenue stream. With that, let me turn the call to Daniel Weinmann, our VP of Finance, to review our results in greater detail. Daniel? Daniel Weinmann Thank you, Marco. I will discuss our consolidated financial results before reviewing our business segment results in more detail. First quarter total revenue was $93.1 million, a 32.1% increase year-over-year compared to $70.5 million for last year's first quarter. The increase in revenue was primarily due to a 36% increase in brokerage revenue as well as an increase in revenue from our ancillary businesses. Excluding the impact of the company's divested insurance business, total gross profit increased by 34% in the first quarter of 2025 compared to the same period in 2024. Gross profit margin remained consistent at 8.7% year-over-year on the same basis. Technology and development expenses were approximately $1.9 million for the first quarter of 2025 compared with $1.6 million for the first quarter of 2024. The approximate $300,000 increase was primarily due to our continued investment in our technology platforms, including the build-out of our new direct-to-agent program at LiveBy and our Elevate program. General and administrative expenses totaled $8.6 million for the first quarter of 2025 compared with $9 million for the first quarter of 2024. The decrease was primarily due to our cost-cutting initiatives. Marketing expenses totaled $1.4 million for the first quarter of 2025 compared with $1.2 million for the first quarter of 2024. The increase was primarily due to investments in our ancillary businesses. GAAP net loss for the first quarter of 2025 totaled $5.6 million or $0.24 per share compared with a loss of $5.9 million or $0.31 per share for the first quarter of 2024. The decrease in net loss was primarily due to our cost saving efforts. Adjusted EBITDA loss, a non-GAAP measure for Q1 2025 remained unchanged at $1.5 million compared to Q1 2024. Now I will spend some time reviewing our business segment results in more detail. We start with our brokerage business. We've closed approximately 9,715 real estate transactions during the first quarter, an increase of 26.1% compared to 7,703 transactions during the first quarter of 2024. The increase in real estate transactions is primarily attributed to the addition of My Home Group. We ended the first quarter with approximately 14,715 agent licenses, an increase of 22.8% compared to 11,986 agents at the end of the first quarter of 2024. Revenue for the Real Estate division was approximately $88.9 million in the first quarter compared to $65.4 million for the same period last year, which represents an increase of 36% and primarily attributed to the addition of My Home Group. Gross profit margin for our Real Estate division improved to 7.1% from 6.5% in the first quarter of 2025 compared to the first quarter of 2024. This increase in margin was largely due to an increase in transactions from non-cap agents and the impact of our agents annual fee increase. Adjusted EBITDA gain in the Real Estate division was approximately $1.6 million in Q1 of 2025, an increase of $800,000 compared to adjusted EBITDA of $800,000 in Q1 of 2024. The improvement was primarily driven by increased revenue and the continued execution of cost-cutting initiatives. Moving on to our Mortgage business. Our mortgage business generated revenues of $2.6 million in Q1 2025 compared to $2.3 million in Q1 of 2024. Mortgage adjusted EBITDA for Q1 2025 was a loss of $400,000 compared to an adjusted EBITDA loss of $500,000 for the same period last year. Adjusted EBITDA loss improved by $100,000 due to continued strategic cost-cutting measures. Moving to our title business. Verus Title had revenues of $1 million for the first quarter of 2025 compared to $700,000 for the first quarter of 2024, an increase of 43%. The increase in revenue was driven by organic growth and walkovers. Verus Title's adjusted EBITDA for the 2024 first quarter was a loss of $400,000 compared to an adjusted EBITDA loss of $200,000 for Q1 2024. Moving to our Technology segment. Third-party revenues decreased to $600,000 in Q1 2025 compared to $800,000 in Q1 2024. Adjusted EBITDA income for the first quarter of 2025 was $50,000 compared to an adjusted EBITDA loss of $30,000 for the first quarter of 2024. Adjusted EBITDA income improved by $80,000 due to continued strategic cost-cutting measures. We continue to keenly focus on our balance sheet given the dynamic real estate market conditions. We ended the quarter with a cash position of $8 million, which includes the $2.7 million in net proceeds from the public offering in March. We did not purchase any shares in the first quarter under the stock repurchase plan. Marco, back to you for final remarks. Marco Fregenal Thank you, Daniel. Before I close, I want to reiterate that we remain focused on 3 core drivers of long-term profitability. First, expanding revenue through strategic growth second, enhancing gross margins through agent programs such as Elevate and ancillary services; and third, continued cost discipline across all areas of the business. In summary, Q1 was a strong start of the year with outperformed analyst expectations, grew across every key metric, launch a high potential new program in Elevate and continue executing against our plan to reach adjusted EBITDA profitability by Q2. While we remain cautious about broader market volatility and global economic uncertainties, we are encouraged by the momentum we are seeing and confident in our ability to adapt and thrive regardless of what rest of the year brings. Thank you again for your continued support and belief in Fathom. And operator, we're now ready to take any questions. Operator (Operator Instructions) Darren Aftahi, ROTH Capital Partners. Darren Aftahi Nice to see the growth there. Marco, I just -- two, if I may, I guess, can you just talk a little bit more in depth about how Elevate enhances the profitability on both gross profit and adjusted EBITDA per transaction with Elevate versus some of your traditional programs. And I know you kind of laid out the goal of 100 agents per month exiting the fourth quarter or into the fourth quarter. Just trying to understand kind of the cadence of the onboarding pipeline of agents that I know you've made a commentary that there could be a positive impact on ancillary business. I'm kind of curious to learn more about that. Marco Fregenal Darren, thank you for your questions. So the -- because we're charging 20% and because of the efficiencies of intelliAgent, we are going to see a higher gross profit margin per transaction. I think we can see gross profit margin grow by 3x to 4x compared to our traditional gross profit margin. And it's really because of the efficiency of our platform and what we can deliver. Second, we launched this internally about 4 weeks ago. and it really was a soft launch. And pretty quickly, there are about 120 agents that signed up. We are already onboarding them into the program. And starting, I think, next week, we'll start marketing externally even though we already had some external agents joining the program. And I think we'll continue to ramp up with the ultimate goal of the end of the year onboarding about 100 agents. We want to be careful about the growth. It is a complex program. And so we want to make sure that we are firing all cylinders. But we think that by the end of the year, we can be at about 100 new agents a month and then, of course, into next year, growing that even further. And so given that the financial results of the program thus far, we feel incredibly positive about the impact it's going to have in gross profit and adjusted EBITDA. Darren Aftahi That's helpful. And just one more, if I may. Outside of My Home Group, have you guys held discussions with similar size agent teams to join Fathom? And has any of that accelerated post the launch of Elevate? I know you talked about some teams and partners in the pipeline. Marco Fregenal Yes. Actually, once we launch Elevate, we absolutely have a lot more conversations with different brokerages, not only brokers but technology partners, brokerages, and we're having a great deal of number of conversations in terms of Elevate. So I do think going forward, we're going to see potentially perhaps into -- more into Q3, more walkovers -- and then I think within the next 6 months, you'll see some announcements in terms of potential partnerships of companies that want to not only partner with Elevate but license Elevate. And so that has been a significant interest from a lot of different companies on what Elevate is. And we're looking forward to continue to expand the program not only into other companies, but into other types of agents. For example, teams is 1 in which we are going to create Elevate for teams, for example. So I think there's a lot of opportunity around Elevate, and I think we are in the very early stages. And I think that they're going to have some significant results in the next 12 to 18 months. Operator (Operator Instructions) There are no further questions in the queue. Marco Fregenal Okay. Thank you, everyone, for joining us today. As always, I look forward to our next update. I hope everyone has a good evening. Thank you for joining us. Operator Thank you. Everyone, this concludes today's event. You may disconnect at this time, and have a wonderful day. Thank you for your participation. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Fathom Holdings Inc (FTHM) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
Total Revenue: $93.1 million, a 32.1% increase year over year. Brokerage Revenue: $88.9 million, up 36% from the previous year. Gross Profit: $8.1 million, a 13% increase year over year. Agent Count: Approximately 14,750, a 22.8% increase over Q1 2024. Real Estate Transactions: 9,715, a 26.1% increase compared to Q1 2024. Mortgage Revenue: $2.6 million, a 13% increase from Q1 2024. Title Revenue: $1 million, a 43% increase from Q1 2024. GAAP Net Loss: $5.6 million or $0.24 per share, compared to a loss of $5.9 million or $0.31 per share in Q1 2024. Adjusted EBITDA Loss: $1.5 million, unchanged from Q1 2024. Cash Position: $8 million at the end of the quarter. Warning! GuruFocus has detected 6 Warning Signs with FTHM. Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Fathom Holdings Inc (NASDAQ:FTHM) reported a 32.1% increase in total revenue for Q1 2025, reaching $93.1 million, exceeding analysts' expectations by 12%. Brokerage revenue climbed nearly 36% to $88.9 million, driven by increased transaction volume and agent count. The company successfully reduced expenses by approximately $750,000 per quarter, contributing to a more efficient and scalable business model. The new Elevate program, designed to enhance agent productivity and profitability, has already attracted over 120 agents since its soft launch. Fathom Holdings Inc (NASDAQ:FTHM) expects to achieve adjusted EBITDA profitability in the second quarter of 2025, marking a significant milestone in its financial performance. Despite revenue growth, Fathom Holdings Inc (NASDAQ:FTHM) reported a GAAP net loss of $5.6 million for Q1 2025, though this was an improvement from the previous year's loss. The company's technology segment saw a decrease in third-party revenues, dropping to $600,000 in Q1 2025 from $800,000 in Q1 2024. The mortgage business reported an adjusted EBITDA loss of $400,000, although this was an improvement from the previous year's loss. Verus Title, part of Fathom's title business, reported an adjusted EBITDA loss of $400,000 for Q1 2025, an increase from the previous year's loss. The company faces ongoing economic headwinds, including elevated mortgage rates and global economic uncertainty, which could impact future performance. Q: Can you elaborate on how the Elevate program enhances profitability on both gross profit and adjusted EBITDA per transaction compared to traditional programs? Also, what is the onboarding pipeline for agents into Elevate? A: Marco Fregenal, CEO, explained that Elevate charges a 20% commission split, and due to the efficiencies of the intelliAgent platform, they expect gross profit margins to grow by 3x to 4x compared to traditional margins. The program had a soft launch four weeks ago, with 120 agents already signed up. They aim to onboard about 100 new agents per month by the end of the year, with a careful approach to growth due to the program's complexity. Q: Outside of My Home Group, have there been discussions with other agent teams to join Fathom, and has the launch of Elevate accelerated these discussions? A: Marco Fregenal confirmed that the launch of Elevate has led to more conversations with brokerages and technology partners. They anticipate more partnerships and potential licensing agreements for Elevate in the coming months, with announcements expected within the next six months. Q: What impact do you expect Elevate to have on ancillary businesses? A: Marco Fregenal noted that Elevate could positively impact ancillary businesses by building closer relationships with participating agents. This could enhance margins, increase agent retention, and contribute to a more diverse revenue stream. Q: How has the market shift from a seller's market to a more balanced market affected Fathom's operations? A: Marco Fregenal mentioned that while mortgage rates remain elevated, they are stabilizing, and housing inventory is increasing. This shift has led to price reductions and longer market times, but Fathom is well-positioned to benefit from any market improvements due to their lean cost structure and value proposition. Q: Can you provide more details on the financial performance of the brokerage and ancillary businesses? A: Daniel Weinmann, VP of Finance, reported that brokerage revenue increased by 36% to $88.9 million, with a 26.1% increase in transactions. Mortgage revenue rose by 13% to $2.6 million, and title revenue increased by 43% to $1 million. These results were driven by strategic growth and cost-cutting initiatives. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
